ICCC - MCAP CO - ImmuCell Corporation

ImmuCell Corporation (ICCC) develops disease prevention tools for livestock and dairy farms, maintaining a dominant position in the calf protection segment. Steady demand for veterinary pharmaceuticals ensures a stable cash flow at the level of 0.09. The price trajectory shown below visualizes the asset's market dynamics. High barriers to entry have been established through stringent USDA requirements and a robust patent system.

The B2B lock-in effect of First Defense antibody supplies establishes a stable value base for ImmuCell Corporation (ICCC). Analyzing the issuer's current market capitalization, an investor sees the total volume of all outstanding shares multiplied by the market price. This indicator measures the total market value of the business, separating the actual scale of the enterprise from speculative expectations. Low metric values create a margin of safety, reducing the cost of error when entering the asset.